Oculus Innovative Sciences Announces U.S. EPA Approval of Microcyn Disinfectant Technology; Patented Electrolysis Process Produces the Worlds First Stable Super-oxidized Water

PETALUMA, Calif. -- Hoji Alimi, founder and president of Oculus Innovative Sciences, today announced that the company has received approval from the U.S. EPA to market the companys first U.S. disinfectant product utilizing the companys Microcyn technology, as a multipurpose, hospital-grade disinfectant cleaner and food contact sanitizer for use on hard, inanimate surfaces. It is a stable, super-oxidized, pH-neutral, non-flammable and non-corrosive bactericidal, tuberculocidal and virucidal solution that is ready for use with no dilution or mixing, and requires no special handling or disposal.


Microcyn is manufactured using a sophisticated, multi-chamber electrolysis process in which ionic species are selectively produced and isolated. This process allows for the production of both a stable and pH-neutral solution while minimizing the level of chlorine in the final product. The federal EPA approval allows the company to market its label claims and enter into negotiations with distributors for commercialization purposes.


The first commercialized product formulated with Microcyn technology for use in the United States will be Cidalcyn Hospital Grade Disinfectant. It will effectively disinfect hard, non-porous surfaces such as non-critical medical devices, surgical beds/tables, dental irrigation equipment, and anesthesia machines. It is also for use in the consumer market.


The company also received CE approval for its Microcyn technology in Europe this past spring and Ministry of Health approval in Mexico in 2003. Oculus introduced its first U.S. product, Vetericyn Wound Spray for animals, also formulated with the patented Microcyn technology, in July.


Oculus Innovative Sciences, headquartered in Petaluma, California, is pioneering innovative life sciences and disruptive technologies that globally re-define the disinfectant and antiseptic markets. With a primary focus on anti-infective and wound management technologies, the company has employees and operations in Mexico, Europe and the U.S. and includes two wholly owned subsidiaries, Oculus Technologies of Mexico, S.A. de C.V., and Oculus Innovative Sciences Netherlands B.V.


Source: Oculus Innovative Sciences